- Home
- COYA vs CRDF Comparison
COYA vs CRDF Comparison
Compare COYA & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | CRDF |
|---|---|---|
| Founded | 2020 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.8M | 114.2M |
| IPO Year | 2022 | 2012 |
Fundamental Metrics
Financial Performance| Metric | COYA | CRDF |
|---|---|---|
| Price | $4.45 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $15.80 | $9.63 |
| AVG Volume (30 Days) | 165.4K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,945,753.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $763.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.57 | 49.61 |
| 52 Week Low | $3.71 | $1.35 |
| 52 Week High | $7.75 | $4.56 |
Technical Indicators
Market Signals| Indicator | COYA | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 43.78 |
| Support Level | $4.50 | $1.49 |
| Resistance Level | $5.18 | $1.76 |
| Average True Range (ATR) | 0.32 | 0.15 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 28.24 | 26.15 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.